BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 273] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Yoo ER, Kim D, Vazquez‐montesino LM, Escober JA, Li AA, Tighe SP, Fernandes CT, Cholankeril G, Ahmed A. Diet quality and its association with nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality. Liver Int 2020;40:815-24. [DOI: 10.1111/liv.14374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 819] [Article Influence: 72.6] [Reference Citation Analysis]
3 Verderese JP, Younossi Z. Interaction of type 2 diabetes and nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2013;7:405-7. [PMID: 23899279 DOI: 10.1586/17474124.2013.811047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist. 2012;17:201-211. [PMID: 22234631 DOI: 10.1634/theoncologist.2011-0300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
5 Tsuneyama K, Nishida T, Baba H, Taira S, Fujimoto M, Nomoto K, Hayashi S, Miwa S, Nakajima T, Sutoh M, Oda E, Hokao R, Imura J. Neonatal monosodium glutamate treatment causes obesity, diabetes, and macrovesicular steatohepatitis with liver nodules in DIAR mice. J Gastroenterol Hepatol 2014;29:1736-43. [PMID: 24730643 DOI: 10.1111/jgh.12610] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kim SW, Hur W, Li TZ, Lee YK, Choi JE, Hong SW, Lyoo KS, You CR, Jung ES, Jung CK, Park T, Um SJ, Yoon SK. Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice. Exp Mol Med 2014;46:e92. [PMID: 24763197 DOI: 10.1038/emm.2014.10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
7 Weiss B, Krauthammer A, Soudack M, Lahad A, Sarouk I, Somech R, Heimer G, Ben-zeev B, Nissenkorn A. Liver Disease in Pediatric Patients With Ataxia Telangiectasia: A Novel Report. Journal of Pediatric Gastroenterology & Nutrition 2016;62:550-5. [DOI: 10.1097/mpg.0000000000001036] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
8 Corbin KD, Abdelmalek MF, Spencer MD, da Costa KA, Galanko JA, Sha W, Suzuki A, Guy CD, Cardona DM, Torquati A, Diehl AM, Zeisel SH. Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis. FASEB J 2013;27:1674-89. [PMID: 23292069 DOI: 10.1096/fj.12-219097] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
9 Hu W, Shao X, Guo D, Hao H, Zhang Y, Xia M, Gong Y, Zhou H, Fan Y, Yu W. Relationship of Serum Betatrophin with Nonalcoholic Fatty Liver in a Chinese Population. PLoS One 2017;12:e0170758. [PMID: 28125672 DOI: 10.1371/journal.pone.0170758] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang P, Lu Z, He M, Shi B, Lei X, Shan A. The Effects of Endoplasmic-Reticulum-Resident Selenoproteins in a Nonalcoholic Fatty Liver Disease Pig Model Induced by a High-Fat Diet. Nutrients 2020;12:E692. [PMID: 32143527 DOI: 10.3390/nu12030692] [Reference Citation Analysis]
11 Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023. [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5] [Cited by in Crossref: 152] [Cited by in F6Publishing: 144] [Article Influence: 16.9] [Reference Citation Analysis]
12 Romanowski MD, Parolin MB, Freitas AC, Piazza MJ, Basso J, Urbanetz AA. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome. Arq Gastroenterol. 2015;52:117-123. [PMID: 26039829 DOI: 10.1590/s0004-28032015000200008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
13 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
14 Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr. 2019;7:96-108. [PMID: 30680163 DOI: 10.1002/fsn3.807] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
15 Klaikeaw N, Wongphoom J, Werawatganon D, Chayanupatkul M, Siriviriyakul P. Anti-inflammatory and anti-oxidant effects of aloe vera in rats with non-alcoholic steatohepatitis. World J Hepatol 2020; 12(7): 363-377 [PMID: 32821335 DOI: 10.4254/wjh.v12.i7.363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
16 Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645-649. [PMID: 20400911 DOI: 10.1097/mpg.0b013e3181c7bdf1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
17 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009; 15(48): 6017-6022 [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
18 Wang Y, Wang H, Deng P, Tao T, Liu H, Wu S, Chen W, Qin J. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System. ACS Biomater Sci Eng 2020;6:5734-43. [DOI: 10.1021/acsbiomaterials.0c00682] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol. 2011;163:1432-1440. [PMID: 21457226 DOI: 10.1111/j.1476-5381.2011.01397.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 7.4] [Reference Citation Analysis]
21 Nakade Y, Sakamoto K, Yamauchi T, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Sumida Y, Ito K, Nakao H, Fukuzawa Y, Umezawa K, Yoneda M. Conophylline inhibits non-alcoholic steatohepatitis in mice. PLoS One 2017;12:e0178436. [PMID: 28594915 DOI: 10.1371/journal.pone.0178436] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
22 Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011;15:485-504. [PMID: 21128703 DOI: 10.1089/ars.2010.3795] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
23 Kappus M, Abdelmalek M. De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation. Clinics in Liver Disease 2017;21:321-35. [DOI: 10.1016/j.cld.2016.12.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
24 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
25 Trujillo-gonzalez I, Zeisel SH. Choline. Present Knowledge in Nutrition. Elsevier; 2020. pp. 305-18. [DOI: 10.1016/b978-0-323-66162-1.00018-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Zhang M, Chi X, Qu N, Wang C. Long noncoding RNA lncARSR promotes hepatic lipogenesis via Akt/SREBP-1c pathway and contributes to the pathogenesis of nonalcoholic steatohepatitis. Biochem Biophys Res Commun 2018;499:66-70. [PMID: 29555473 DOI: 10.1016/j.bbrc.2018.03.127] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
27 Auguet T, Berlanga A, Guiu-Jurado E, Terra X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernández M, Del Castillo D, Richart C. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed Res Int 2014;2014:502542. [PMID: 24864249 DOI: 10.1155/2014/502542] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
28 Barr RG. Invited Commentary on “Elastography in Chronic Liver Disease”. RadioGraphics 2016;36:2007-9. [DOI: 10.1148/rg.2016160182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol 2015; 7(10): 1297-1301 [PMID: 26052375 DOI: 10.4254/wjh.v7.i10.1297] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
30 Newsome PN. Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome? Liver Transpl 2010;16:420-2. [PMID: 20373452 DOI: 10.1002/lt.22038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
31 Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19-31. [PMID: 24274862 DOI: 10.1016/j.cld.2013.09.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
32 Monteiro J, Askarian F, Nakamura MT, Moghadasian MH, Ma DW. Oils rich in α-linolenic acid independently protect against characteristics of fatty liver disease in the Δ6-desaturase null mouse. Can J Physiol Pharmacol 2013;91:469-79. [DOI: 10.1139/cjpp-2012-0308] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
33 Serhal R, Hilal G, Boutros G, Sidaoui J, Wardi L, Ezzeddine S, Alaaeddine N. Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. Biomed Res Int 2015;2015:850246. [PMID: 26273651 DOI: 10.1155/2015/850246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
34 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 8.3] [Reference Citation Analysis]
35 Spielman DM, Mayer D, Yen YF, Tropp J, Hurd RE, Pfefferbaum A. In vivo measurement of ethanol metabolism in the rat liver using magnetic resonance spectroscopy of hyperpolarized [1-13C]pyruvate. Magn Reson Med 2009;62:307-13. [PMID: 19526498 DOI: 10.1002/mrm.21998] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
36 Wang Z, Yao T, Song Z. Extracellular signal-regulated kinases 1/2 suppression aggravates transforming growth factor-beta1 hepatotoxicity: a potential mechanism for liver injury in methionine-choline deficient-diet-fed mice. Exp Biol Med (Maywood) 2010;235:1347-55. [PMID: 20962016 DOI: 10.1258/ebm.2010.010160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
37 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379. [PMID: 22517736 DOI: 10.2337/dc12-0413] [Cited by in Crossref: 2335] [Cited by in F6Publishing: 1983] [Article Influence: 233.5] [Reference Citation Analysis]
38 Silverman RB. Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.1c00526] [Reference Citation Analysis]
39 Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210. [PMID: 25884354 DOI: 10.1186/s12885-015-1197-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
40 Salehi-Sahlabadi A, Mokari A, Elhamkia M, Farahmand F, Jabbari M, Hekmatdost A. Dietary Total Antioxidant Capacity and Risk of Non-Alcoholic Fatty Liver Disease: A Case-Control Study. J Res Health Sci 2020;20:e00486. [PMID: 33169718 DOI: 10.34172/jrhs.2020.18] [Reference Citation Analysis]
41 Nakade Y, Murotani K, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Ito K, Fukuzawa Y, Yoneda M. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47:1417-1428. [PMID: 28257594 DOI: 10.1111/hepr.12887] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
42 Zhuge B, Li G. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. Biochemical and Biophysical Research Communications 2017;494:687-92. [DOI: 10.1016/j.bbrc.2017.10.149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
43 Banderas DZ, Escobedo J, Gonzalez E, Liceaga MG, Ramírez JC, Castro MG. γ-Glutamyl transferase: a marker of nonalcoholic fatty liver disease in patients with the metabolic syndrome. Eur J Gastroenterol Hepatol. 2012;24:805-810. [PMID: 22546752 DOI: 10.1097/meg.0b013e328354044a] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
44 Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D. Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017; 8(2): 67-76 [PMID: 28573069 DOI: 10.4291/wjgp.v8.i2.67] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Linhart KB, Glassen K, Peccerella T, Waldherr R, Linhart H, Bartsch H, Seitz HK. The generation of carcinogenic etheno-DNA adducts in the liver of patients with nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2015;4:117-23. [PMID: 26005678 DOI: 10.3978/j.issn.2304-3881.2015.01.14] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
46 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1016/s1665-2681(19)31820-4] [Cited by in Crossref: 188] [Cited by in F6Publishing: 1] [Article Influence: 14.5] [Reference Citation Analysis]
47 Ivanovic N, Minic R, Dimitrijevic L, Radojevic Skodric S, Zivkovic I, Djordjevic B. Lactobacillus rhamnosus LA68 and Lactobacillus plantarum WCFS1 differently influence metabolic and immunological parameters in high fat diet-induced hypercholesterolemia and hepatic steatosis. Food Funct 2015;6:558-65. [DOI: 10.1039/c4fo00843j] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 3.1] [Reference Citation Analysis]
48 Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N;  Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology. 2012;55:769-780. [PMID: 21987488 DOI: 10.1002/hep.24726] [Cited by in Crossref: 130] [Cited by in F6Publishing: 125] [Article Influence: 13.0] [Reference Citation Analysis]
49 Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. The Oncologist 2009;14:1095-105. [DOI: 10.1634/theoncologist.2009-0152] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
50 de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2008;11:267-274. [PMID: 18403923 DOI: 10.1097/mco.0b013e3282fbd33f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
51 Hearn C, Ellington BJ, Jones R. The Role of the Nurse Practitioner in the Management of Nonalcoholic Fatty Liver Disease. Gastroenterol Nurs 2018;41:424-6. [PMID: 30272604 DOI: 10.1097/SGA.0000000000000394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: A meta-analysis. World J Gastroenterol 2014; 20(2): 569-577 [PMID: 24574727 DOI: 10.3748/wjg.v20.i2.569] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
53 Lee S, Kwak JH, Kim SH, Jeong TB, Son SW, Kim JH, Lim Y, Cho JY, Hwang DY, Kim KS, Jung YS. Comparative study of liver injury induced by high-fat methionine- and choline-deficient diet in ICR mice originating from three different sources. Lab Anim Res 2019;35:15. [PMID: 32257903 DOI: 10.1186/s42826-019-0016-y] [Reference Citation Analysis]
54 Lalazar G, Zigmond E, Weksler-zangen S, Ya'acov AB, Levy MS, Hemed N, Raz I, Ilan Y. Oral Administration of β -Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. Journal of Medicinal Food 2017;20:458-64. [DOI: 10.1089/jmf.2016.3753] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
55 Lee SW, Lee TY, Yang SS, Tung CF, Yeh HZ, Chang CS. Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. Hepatobiliary Pancreat Dis Int. 2018;17:45-48. [PMID: 29428103 DOI: 10.1016/j.hbpd.2018.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
56 Carter D, Dieterich DT, Chang C. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clin Liver Dis 2018;22:213-27. [PMID: 29128058 DOI: 10.1016/j.cld.2017.08.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
57 El-Masry M, Puig CA, Saab S. Recurrence of non-viral liver disease after orthotopic liver transplantation. Liver Int. 2011;31:291-302. [PMID: 21281429 DOI: 10.1111/j.1478-3231.2010.02434.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
58 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 145] [Article Influence: 29.2] [Reference Citation Analysis]
59 Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292-299. [PMID: 23512725 DOI: 10.1002/oby.20426] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 8.0] [Reference Citation Analysis]
60 Le TA, Loomba R. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. J Clin Exp Hepatol 2012;2:156-73. [PMID: 25755424 DOI: 10.1016/S0973-6883(12)60104-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
61 Pimentel CF, Lai M. Nutrition Interventions for Chronic Liver Diseases and Nonalcoholic Fatty Liver Disease. Med Clin North Am. 2016;100:1303-1327. [PMID: 27745596 DOI: 10.1016/j.mcna.2016.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
62 Pires LB, Rocha R, Vargas D, Daltro C, Cotrim HP. Non-alcoholic fatty liver disease in patients infected with human immunodeficiency virus: a systematic review. Rev Assoc Med Bras (1992) 2020;66:81-6. [PMID: 32130386 DOI: 10.1590/1806-9282.66.1.81] [Reference Citation Analysis]
63 Xie X, Feng Y, Lyu Z, Wang L, Yang Y, Bai Y, Liu C, Wu H, Ren W, Zhu Q. Liver stiffness as measured by two-dimensional shear wave elastography overestimates the stage of fibrosis in patients with chronic hepatitis B and hepatic steatosis. Clin Res Hepatol Gastroenterol 2021;45:101421. [PMID: 32312597 DOI: 10.1016/j.clinre.2020.03.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011;359-364. [PMID: 22755431 DOI: 10.1111/j.1399-0012.2010.01305.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
65 Parente DB, Rodrigues RS, Paiva FF, Oliveira Neto JA, Machado-Silva L, Lanzoni V, Campos CF, Eiras-Araujo AL, do Brasil PE, Garteiser P, Gomes MB, de Mello Perez R. Is MR spectroscopy really the best MR-based method for the evaluation of fatty liver in diabetic patients in clinical practice? PLoS One 2014;9:e112574. [PMID: 25426708 DOI: 10.1371/journal.pone.0112574] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
66 Satapathy SK, Jiang Y, Eason JD, Kedia SK, Wong E, Singal AK, Tolley EA, Hathaway D, Nair S, Vanatta JM. Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States-a retrospective study. Transpl Int 2017;30:1051-60. [DOI: 10.1111/tri.13001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Al-Nowaylati AR, Al-Haddad BJ, Dorman RB, Alsaied OA, Lake JR, Chinnakotla S, Slusarek BM, Sampson BK, Ikramuddin S, Buchwald H, Leslie DB. Gastric bypass after liver transplantation. Liver Transpl. 2013;19:1324-1329. [PMID: 24039124 DOI: 10.1002/lt.23734] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.9] [Reference Citation Analysis]
68 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
69 Paraiso IL, Revel JS, Choi J, Miranda CL, Lak P, Kioussi C, Bobe G, Gombart AF, Raber J, Maier CS, Stevens JF. Targeting the Liver‐Brain Axis with Hop‐Derived Flavonoids Improves Lipid Metabolism and Cognitive Performance in Mice. Mol Nutr Food Res 2020;64:2000341. [DOI: 10.1002/mnfr.202000341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
70 Wang SN, Wang ST, Lee KT. The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract 2011;2011:215986. [PMID: 21960997 DOI: 10.1155/2011/215986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
71 Yang MH, Sung J, Gwak G. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. Journal of Clinical Lipidology 2016;10:289-98. [DOI: 10.1016/j.jacl.2015.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
72 Ip S, Bhanji RA, Ebadi M, Mason AL, Montano-Loza AJ. De novo and recurrent liver disease. Best Pract Res Clin Gastroenterol 2020;46-47:101688. [PMID: 33158472 DOI: 10.1016/j.bpg.2020.101688] [Reference Citation Analysis]
73 Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2019;1864:158523. [DOI: 10.1016/j.bbalip.2019.158523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
74 Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol. 2011;9:154. [PMID: 22115124 DOI: 10.1186/1477-7819-9-154] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
75 Arrese M. Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease. Hepatology. 2009;49:348-351. [PMID: 19177580 DOI: 10.1002/hep.22783] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
76 Della Fazia MA, Servillo G. Foie gras and liver regeneration: a fat dilemma. Cell Stress 2018;2:162-75. [PMID: 31225483 DOI: 10.15698/cst2018.07.144] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
77 Hansel C, Erschfeld S, Baues M, Lammers T, Weiskirchen R, Trautwein C, Kroy DC, Drescher HK. The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis. Front Pharmacol 2019;10:244. [PMID: 30949049 DOI: 10.3389/fphar.2019.00244] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Ghosh S, Kaw M, Patel PR, Ledford KJ, Bowman TA, McInerney MF, Erickson SK, Bourey RE, Najjar SM. Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. Hepat Med 2010;2010:69-78. [PMID: 21949477 DOI: 10.2147/HMER.S8902] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
79 Honda Y, Imajo K, Kobayashi T, Kessoku T, Ogawa Y, Tomeno W, Yoneda M, Kobayashi N, Saito S, Nakajima A. Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2019;49:1136-46. [PMID: 31144415 DOI: 10.1111/hepr.13382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
80 Shen HC, Zhao ZH, Hu YC, Chen YF, Tung TH. Relationship between obesity, metabolic syndrome, and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan. Clin Interv Aging 2014;9:501-8. [PMID: 24741297 DOI: 10.2147/CIA.S59538] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
81 Jung ES, Lee K, Yu E, Kang YK, Cho MY, Kim JM, Moon WS, Jeong JS, Park CK, Park JB, Kang DY, Sohn JH, Jin SY. Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease. J Pathol Transl Med 2016;50:190-6. [PMID: 27086596 DOI: 10.4132/jptm.2016.03.01] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
82 Tsutsui M, Tanaka N, Kawakubo M, Sheena Y, Horiuchi A, Komatsu M, Nagaya T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Aoyama T, Tanaka E, Sano K. Serum Fragmented Cytokeratin 18 Levels Reflect the Histologic Activity Score of Nonalcoholic Fatty Liver Disease More Accurately Than Serum Alanine Aminotransferase Levels. Journal of Clinical Gastroenterology 2010;44:440-7. [DOI: 10.1097/mcg.0b013e3181bdefe2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 34] [Article Influence: 1.2] [Reference Citation Analysis]
83 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365. [PMID: 23175136 DOI: 10.1002/hep.26156] [Cited by in Crossref: 410] [Cited by in F6Publishing: 382] [Article Influence: 45.6] [Reference Citation Analysis]
84 Pimentel CF, Jiang ZG, Otsubo T, Feldbrügge L, Challies TL, Nasser I, Robson S, Afdhal N, Lai M. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Dig Dis Sci 2016;61:905-12. [PMID: 26462489 DOI: 10.1007/s10620-015-3916-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
85 Parsi A, Torkashvand M, Hajiani E, Rahimlou M, Sadeghi N. The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. Obesity Medicine 2020;17:100165. [DOI: 10.1016/j.obmed.2019.100165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
86 Iruzubieta P, Terán &, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol 2014; 6(12): 901-915 [PMID: 25544877 DOI: 10.4254/wjh.v6.i12.901] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
87 Zhang N, Lei J, Lei H, Ruan X, Liu Q, Chen Y, Huang W. MicroRNA-101 overexpression by IL-6 and TNF-α inhibits cholesterol efflux by suppressing ATP-binding cassette transporter A1 expression. Exp Cell Res 2015;336:33-42. [PMID: 26033364 DOI: 10.1016/j.yexcr.2015.05.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
88 Sung YK, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. A case of nonalcoholic steatohepatitis and small intestinal bacterial overgrowth with peripheral edema caused by intestinal bypass surgery and relieved by repair. Gut Liver 2012;6:520-3. [PMID: 23170161 DOI: 10.5009/gnl.2012.6.4.520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
89 Ai Z, Zhu C, Min M, Wang J, Lan C, Fan L, Sun W, Chen D. The Role of Hepatic Liver X Receptor α-and Sterol Regulatory Element Binding Protein-1c-Mediated Lipid Disorder in the Pathogenesis of Non-Alcoholic Steatohepatitis in Rats. J Int Med Res 2011;39:1219-29. [DOI: 10.1177/147323001103900410] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
90 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 6.7] [Reference Citation Analysis]
91 Shen Z, Li Y, Yu C, Shen Y, Xu L, Xu C, Xu G. A cohort study of the effect of alcohol consumption and obesity on serum liver enzyme levels. Eur J Gastroenterol Hepatol. 2010;22:820-825. [PMID: 19829121 DOI: 10.1097/meg.0b013e3283328b86] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
92 Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan JL, Spada A, Hagerty DT, Schiff E. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:64-73. [PMID: 30430605 DOI: 10.1111/apt.15030] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
93 Castaño-Rodríguez N, Mitchell HM, Kaakoush NO. NAFLD, Helicobacter species and the intestinal microbiome. Best Pract Res Clin Gastroenterol 2017;31:657-68. [PMID: 29566909 DOI: 10.1016/j.bpg.2017.09.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
94 Casagrande BP, Gomes MFP, Moura EOC, Santos ACC, Kubota MC, Ribeiro DA, Pisani LP, Medeiros A, Estadella D. Age-dependent hepatic alterations induced by a high-fat high-fructose diet. Inflamm Res 2019;68:359-68. [PMID: 30874869 DOI: 10.1007/s00011-019-01223-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
95 Spahis S, Alvarez F, Dubois J, Ahmed N, Peretti N, Levy E. Plasma fatty acid composition in French-Canadian children with non-alcoholic fatty liver disease: Effect of n-3 PUFA supplementation. Prostaglandins Leukot Essent Fatty Acids. 2015;99:25-34. [PMID: 26066299 DOI: 10.1016/j.plefa.2015.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
96 Nishida T, Tsuneyama K, Fujimoto M, Nomoto K, Hayashi S, Miwa S, Nakajima T, Nakanishi Y, Sasaki Y, Suzuki W. Spontaneous onset of nonalcoholic steatohepatitis and hepatocellular carcinoma in a mouse model of metabolic syndrome. Lab Invest. 2013;93:230-241. [PMID: 23212097 DOI: 10.1038/labinvest.2012.155] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
97 Zhang J, Dai EH, Jiang HQ. Role of the endocannabinoid system in the pathogenesis of cirrhosis. Shijie Huaren Xiaohua Zazhi 2012; 20(13): 1112-1117 [DOI: 10.11569/wcjd.v20.i13.1112] [Reference Citation Analysis]
98 Li P, Li CP. Role of hepatocyte apoptosis in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2008; 16(20): 2253-2258 [DOI: 10.11569/wcjd.v16.i20.2253] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
99 Hakkak R, Bell A, Korourian S. Dehydroepiandrosterone (DHEA) Feeding Protects Liver Steatosis in Obese Breast Cancer Rat Model. Sci Pharm 2017;85:E13. [PMID: 28335515 DOI: 10.3390/scipharm85010013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
100 Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2015;276:845-61. [PMID: 26079489 DOI: 10.1148/radiol.2015150619] [Cited by in Crossref: 276] [Cited by in F6Publishing: 238] [Article Influence: 39.4] [Reference Citation Analysis]
101 Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121-37. [PMID: 21180596 DOI: 10.1177/1756283X09359964] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
102 Fuchs M. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Curr Treat Options Gastro 2015;13:259-73. [DOI: 10.1007/s11938-015-0053-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Patel P, Muller C, Paul S. Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis. World J Hepatol 2020; 12(8): 506-518 [PMID: 32952877 DOI: 10.4254/wjh.v12.i8.506] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
104 Zeisel SH. Nutrition in pregnancy: the argument for including a source of choline. Int J Womens Health 2013;5:193-9. [PMID: 23637565 DOI: 10.2147/IJWH.S36610] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
105 Nakanishi Y, Tsuneyama K, Nomoto K, Fujimoto M, Salunga TL, Nakajima T, Miwa S, Murai Y, Hayashi S, Kato I. Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol Res. 2008;38:1241-1251. [PMID: 18637146 DOI: 10.1111/j.1872-034x.2008.00395.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
106 Mizrahi M, Ben Ya'acov A, Adar T, Levy Sklair M, Gaska S, Ilan Y. Oral Administration of Hoodia parviflora Alleviates Insulin Resistance and Nonalcoholic Steatohepatitis. Journal of Medicinal Food 2019;22:1189-98. [DOI: 10.1089/jmf.2019.0093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
107 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596. [PMID: 22526604 DOI: 10.1007/s00125-012-2534-0] [Cited by in Crossref: 968] [Cited by in F6Publishing: 806] [Article Influence: 96.8] [Reference Citation Analysis]
108 Boonchaya-anant P, Hardy E, Borg BB, Burshell AL. Bone mineral density in patients with nonalcoholic steatohepatitis among end-stage liver disease patients awaiting liver transplantation. Endocr Pract. 2013;19:414-419. [PMID: 23337159 DOI: 10.4158/ep12319.or] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
109 Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132. [PMID: 22126026 DOI: 10.1016/b978-0-12-387042-1.00006-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
110 Wang D, Wang L, Wang Z, Chen S, Ni Y, Jiang D. Higher non-HDL-cholesterol to HDL-cholesterol ratio linked with increased nonalcoholic steatohepatitis. Lipids Health Dis 2018;17:67. [PMID: 29615042 DOI: 10.1186/s12944-018-0720-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
111 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
112 Zhu H, Jr HCB, Clain DJ, Min AD, Theise ND. Hepatic lipogranulomas in patients with chronic liver disease: Association with hepatitis C and fatty liver disease. World J Gastroenterol 2010; 16(40): 5065-5069 [PMID: 20976843 DOI: 10.3748/wjg.v16.i40.5065] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
113 Crawford DHG, Ross DGF, Jaskowski LA, Burke LJ, Britton LJ, Musgrave N, Briskey D, Rishi G, Bridle KR, Subramaniam VN. Iron depletion attenuates steatosis in a mouse model of non-alcoholic fatty liver disease: Role of iron-dependent pathways. Biochim Biophys Acta Mol Basis Dis 2021;1867:166142. [PMID: 33839281 DOI: 10.1016/j.bbadis.2021.166142] [Reference Citation Analysis]
114 Tiniakos DG. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol Clin Biol. 2009;33:930-939. [PMID: 19646834 DOI: 10.1016/j.gcb.2009.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
115 Caraceni P, Domenicali M, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab. 2009;23:65-77. [PMID: 19285261 DOI: 10.1016/j.beem.2008.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
116 Deeken-Draisey A, Rao SM, Yang GY. Pathology in Patients with Chronic Liver Disease: A Practical Approach to Liver Biopsy Interpretation in Patients with Acute and Chronic Liver Diseases. Clin Liver Dis 2020;24:361-72. [PMID: 32620277 DOI: 10.1016/j.cld.2020.04.001] [Reference Citation Analysis]
117 Fujimoto M, Tsuneyama K, Fujimoto T, Selmi C, Gershwin ME, Shimada Y. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 2012;44:767-74. [PMID: 22444524 DOI: 10.1016/j.dld.2012.02.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
118 Chen Q, Xiong C, Jia K, Jin J, Li Z, Huang Y, Liu Y, Wang L, Luo H, Li H, Meng QH, Li W. Hepatic transcriptome analysis from HFD-fed mice defines a long noncoding RNA regulating cellular cholesterol levels. J Lipid Res 2019;60:341-52. [PMID: 30504232 DOI: 10.1194/jlr.M086215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, de Càssia Silva R, Mattos Â, Pereira L, Amorim W, Ivantes C, Souza F, Costa M, Maia L, Pessoa M, Oliveira F. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Annals of Hepatology 2011;10:33-7. [DOI: 10.1016/s1665-2681(19)31584-4] [Cited by in Crossref: 33] [Article Influence: 3.0] [Reference Citation Analysis]
120 Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716-2717. [PMID: 18042105 DOI: 10.1111/j.1572-0241.2007.01520.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 8.0] [Reference Citation Analysis]
121 Conjeevaram HS, Tiniakos DG. Exercise for NAFLD: Does Intensity Matter? American Journal of Gastroenterology 2011;106:470-5. [DOI: 10.1038/ajg.2010.496] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
122 Ogawa Y, Honda Y, Kessoku T, Tomeno W, Imajo K, Yoneda M, Kawanaka M, Kirikoshi H, Ono M, Taguri M, Saito S, Yamanaka T, Wada K, Nakajima A. Wisteria floribunda agglutinin-positive Mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2018;33:1795-1803. [PMID: 29633352 DOI: 10.1111/jgh.14156] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
123 Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:947-55. [PMID: 32780094 DOI: 10.1093/ibd/izaa189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
124 Monsour HP Jr, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2012;8:21-5. [PMID: 23227282 DOI: 10.14797/mdcj-8-3-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
125 Kondo Y, Hasegawa G, Okada H, Senmaru T, Fukui M, Nakamura N, Sawada M, Kitawaki J, Okanoue T, Kishimoto Y, Amano A, Maruyama N, Obayashi H, Ishigami A. Lepr(db/db) Mice with senescence marker protein-30 knockout (Lepr(db/db)Smp30(Y/-)) exhibit increases in small dense-LDL and severe fatty liver despite being fed a standard diet. PLoS One 2013;8:e65698. [PMID: 23755269 DOI: 10.1371/journal.pone.0065698] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
126 Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608-612. [PMID: 18682312 DOI: 10.1016/j.jhep.2008.06.018] [Cited by in Crossref: 417] [Cited by in F6Publishing: 392] [Article Influence: 29.8] [Reference Citation Analysis]
127 Donadon M, Fontana A, Palmisano A, Viganò L, Procopio F, Cimino M, Del Fabbro D, Torzilli G. Individualized risk estimation for postoperative morbidity after hepatectomy: the Humanitas score. HPB 2017;19:910-8. [DOI: 10.1016/j.hpb.2017.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
128 Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano A, Fargion S. Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0162473. [PMID: 27627804 DOI: 10.1371/journal.pone.0162473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
129 Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016; 22(16): 4079-4090 [PMID: 27122660 DOI: 10.3748/wjg.v22.i16.4079] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
130 AlSharari SD, Al-Rejaie SS, Abuohashish HM, Ahmed MM, Hafez MM. Rutin Attenuates Hepatotoxicity in High-Cholesterol-Diet-Fed Rats. Oxid Med Cell Longev 2016;2016:5436745. [PMID: 27239252 DOI: 10.1155/2016/5436745] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
131 Middleton JP, Wiener RC, Barnes BH, Gurka MJ, DeBoer MD. Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening. Clin Pediatr (Phila) 2014;53:1318-25. [PMID: 24477713 DOI: 10.1177/0009922813520072] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
132 Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78. [PMID: 21111705 DOI: 10.1016/j.bbabio.2010.11.004] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
133 Zang S, Wang L, Ma X, Zhu G, Zhuang Z, Xun Y, Zhao F, Yang W, Liu J, Luo Y, Liu Y, Ye D, Shi J. Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis via Neutrophil Elastase in Mice. Cell Biochem Biophys 2015;73:479-87. [PMID: 27352342 DOI: 10.1007/s12013-015-0682-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
134 Page J. Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. J Am Acad Nurse Pract. 2012;24:345-351. [PMID: 22672485 DOI: 10.1111/j.1745-7599.2012.00716.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
135 Nakade Y, Kitano R, Sakamoto K, Kimoto S, Yamauchi T, Inoue T, Kobayashi Y, Ohashi T, Sumida Y, Ito K, Yoneda M. Characteristics of bile acid composition in high fat diet-induced nonalcoholic fatty liver disease in obese diabetic rats. PLoS One 2021;16:e0247303. [PMID: 33626072 DOI: 10.1371/journal.pone.0247303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
137 ASGE Bariatric Endoscopy Task Force. ASGE Technology Committee, Abu Dayyeh BK, Edmundowicz SA, Jonnalagadda S, Kumar N, Larsen M, Sullivan S, Thompson CC, Banerjee S. Endoscopic bariatric therapies. Gastrointest Endosc. 2015;81:1073-1086. [PMID: 25828245 DOI: 10.1016/j.gie.2015.02.023] [Cited by in Crossref: 93] [Cited by in F6Publishing: 62] [Article Influence: 13.3] [Reference Citation Analysis]
138 Austermann C, Schierwagen R, Mohr R, Anadol E, Klein S, Pohlmann A, Jansen C, Strassburg CP, Schwarze-Zander C, Boesecke C, Rockstroh JK, Odenthal M, Trebicka J. microRNA-200a: A stage-dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients. Hepatol Commun 2017;1:36-45. [PMID: 29404431 DOI: 10.1002/hep4.1017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
139 Parikh N, Ahmad J. Nonalcoholic fatty liver disease: pharmacologic and surgical options. Gastroenterol Clin North Am 2011;40:541-59. [PMID: 21893273 DOI: 10.1016/j.gtc.2011.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
140 Pasarín M, Abraldes JG, Rodríguez-vilarrupla A, La Mura V, García-pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. Journal of Hepatology 2011;55:1095-102. [DOI: 10.1016/j.jhep.2011.01.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
141 Rehm JL, Wolfgram PM, Hernando D, Eickhoff JC, Allen DB, Reeder SB. Proton density fat-fraction is an accurate biomarker of hepatic steatosis in adolescent girls and young women. Eur Radiol. 2015;25:2921-2930. [PMID: 25916386 DOI: 10.1007/s00330-015-3724-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
142 Abildgaard A, Solskov L, Volke V, Harvey BH, Lund S, Wegener G. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. Psychoneuroendocrinology 2011;36:623-33. [DOI: 10.1016/j.psyneuen.2010.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
143 Méndez-Sánchez N, Cerda-Reyes E, Higuera-de-la-Tijera F, Salas-García AK, Cabrera-Palma S, Cabrera-Álvarez G, Cortez-Hernández C, Pérez-Arredondo LA, Purón-González E, Coronado-Alejandro E, Panduro A, Rodríguez-Hernández H, Cruz-Ramón VC, Valencia-Rodríguez A, Qi X, Hamdan-Pérez N, Aguilar-Olivos NE, Barranco-Fragoso B, Ramírez-Pérez O, Vera-Barajas A. Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis. F1000Res 2020;9:56. [PMID: 32595949 DOI: 10.12688/f1000research.21918.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
144 Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58:2809-2816. [PMID: 23843097 DOI: 10.1007/s10620-013-2740-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
145 Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis. Transplantation. 2019;103:e345-e354. [PMID: 31415032 DOI: 10.1097/tp.0000000000002916] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 9.5] [Reference Citation Analysis]
146 Eslamparast T, Tandon P, Raman M. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28933748 DOI: 10.3390/nu9080800] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
147 Takano K, Fuji S, Uchida N, Ogawa H, Ohashi K, Eto T, Sakamaki H, Morishima Y, Kato K, Suzuki R, Fukuda T. Pre-transplant diabetes mellitus is a risk factor for non-relapse mortality, especially infection-related mortality, after allogeneic hematopoietic SCT. Bone Marrow Transplant 2015;50:553-8. [PMID: 25621798 DOI: 10.1038/bmt.2014.315] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
148 Yang Y, Kim B, Park YK, Koo SI, Lee JY. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochim Biophys Acta. 2015;1850:178-185. [PMID: 25450180 DOI: 10.1016/j.bbagen.2014.10.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
149 An GH, Lee J, Jin X, Chung J, Kim JC, Park JH, Kim M, Han C, Kim JH, Woo DH. Truncated Milk Fat Globule-EGF-like Factor 8 Ameliorates Liver Fibrosis via Inhibition of Integrin-TGFβ Receptor Interaction. Biomedicines 2021;9:1529. [PMID: 34829758 DOI: 10.3390/biomedicines9111529] [Reference Citation Analysis]
150 Zhai HL, Wang NJ, Han B, Li Q, Chen Y, Zhu CF, Chen YC, Xia FZ, Cang Z, Zhu CX, Lu M, Lu YL. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: A cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr. 2016;115:1352-1359. [PMID: 26888280 DOI: 10.1017/s0007114516000386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
151 Kennedy C, Redden D, Gray S, Eckhoff D, Massoud O, McGuire B, Alkurdi B, Bloomer J, DuBay DA. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford). 2012;14:625-634. [PMID: 22882200 DOI: 10.1111/j.1477-2574.2012.00497.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
152 Alisi A, Manco M, Vania A, Nobili V. Pediatric Nonalcoholic Fatty Liver Disease in 2009. The Journal of Pediatrics 2009;155:469-74. [DOI: 10.1016/j.jpeds.2009.06.014] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
153 Hakkak R, Zeng H, Dhakal IB, Korourian S. Short- and Long-Term Soy Diet Versus Casein Protects Liver Steatosis Independent of the Arginine Content. Journal of Medicinal Food 2015;18:1274-80. [DOI: 10.1089/jmf.2015.0002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
154 Ashla AA, Hoshikawa Y, Tsuchiya H, Hashiguchi K, Enjoji M, Nakamuta M, Taketomi A, Maehara Y, Shomori K, Kurimasa A, Hisatome I, Ito H, Shiota G. Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease. Hepatol Res 2010;40:594-604. [PMID: 20618457 DOI: 10.1111/j.1872-034X.2010.00646.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
155 da Silva RP, Leonard KA, Jacobs RL. Dietary creatine supplementation lowers hepatic triacylglycerol by increasing lipoprotein secretion in rats fed high-fat diet. J Nutr Biochem 2017;50:46-53. [PMID: 29031242 DOI: 10.1016/j.jnutbio.2017.08.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
156 Chen C, Zhang C, Wang X, Zhang F, Zhang Z, Ma P, Feng S. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome. Eur J Gastroenterol Hepatol 2020;32:857-66. [PMID: 31714387 DOI: 10.1097/MEG.0000000000001601] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
157 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
158 Daniel S, Soleymani T, Garvey WT. A complications-based clinical staging of obesity to guide treatment modality and intensity. Curr Opin Endocrinol Diabetes Obes 2013;20:377-88. [PMID: 23974764 DOI: 10.1097/01.med.0000433067.01671.f5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
159 Tor J, Muga R. El hígado graso y el síndrome metabólico. Medicina Clínica 2013;141:252-3. [DOI: 10.1016/j.medcli.2013.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
160 Shidfar F, Bahrololumi SS, Doaei S, Mohammadzadeh A, Gholamalizadeh M, Mohammadimanesh A. The Effects of Extra Virgin Olive Oil on Alanine Aminotransferase, Aspartate Aminotransferase, and Ultrasonographic Indices of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients Undergoing Low Calorie Diet. Can J Gastroenterol Hepatol 2018;2018:1053710. [PMID: 29850450 DOI: 10.1155/2018/1053710] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
161 Jiang T, Chen X, Xia C, Liu H, Yan H, Wang G, Wu Z. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease in North Chinese: a cross-sectional study. Sci Rep 2019;9:4874. [PMID: 30890750 DOI: 10.1038/s41598-019-41371-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
162 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease progression modelling for economic evaluation in non-alcoholic fatty liver disease - a systematic review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01153-8. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Reference Citation Analysis]
163 Hossain N, Stepanova M, Afendy A, Nader F, Younossi Y, Rafiq N, Goodman Z, Younossi ZM. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand J Gastroenterol. 2011;46:479-484. [PMID: 21114431 DOI: 10.3109/00365521.2010.539251] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
164 Shen H, Liu T, Zhang L, Zheng PY, Ji G, Xing LJ. Pathogenesis of increased sensitivity of hepatocytes to injury in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2010; 18(7): 685-688 [DOI: 10.11569/wcjd.v18.i7.685] [Reference Citation Analysis]
165 Kang SJ, Kim HJ, Kim D, Ahmed A. Association between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United States. PLoS One 2018;13:e0202325. [PMID: 30110395 DOI: 10.1371/journal.pone.0202325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
166 Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. [PMID: 26666336 DOI: 10.1186/s12876-015-0407-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
167 Crawford JM, Liu C. Liver and Biliary Tract. Robbins and Cotran Pathologic Basis of Disease. Elsevier; 2010. pp. 833-90. [DOI: 10.1016/b978-1-4377-0792-2.50023-7] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
168 Pinzani M. Hepatic Fibrosis. Stellate Cells in Health and Disease. Elsevier; 2015. pp. 29-39. [DOI: 10.1016/b978-0-12-800134-9.00003-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Khoury T, Mari A, Nseir W, Kadah A, Sbeit W, Mahamid M. Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2019;31:1110-1115. [PMID: 30888972 DOI: 10.1097/meg.0000000000001393] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
170 Pusl T, Wild N, Vennegeerts T, Wimmer R, Göke B, Brand S, Rust C. Free fatty acids sensitize hepatocytes to bile acid-induced apoptosis. Biochem Biophys Res Commun 2008;371:441-5. [PMID: 18452708 DOI: 10.1016/j.bbrc.2008.04.113] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
171 Aboulmagd YM, El-Bahy AAZ, Menze ET, Azab SS, El-Demerdash E. Role of linagliptin in preventing the pathological progression of hepatic fibrosis in high fat diet and streptozotocin-induced diabetic obese rats. Eur J Pharmacol 2020;881:173224. [PMID: 32454118 DOI: 10.1016/j.ejphar.2020.173224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Kim D, Cholankeril G, Li AA, Kim W, Tighe SP, Hameed B, Kwo PY, Harrison SA, Younossi ZM, Ahmed A. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014. Liver Int 2019;39:1661-71. [PMID: 31081997 DOI: 10.1111/liv.14135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
173 Erstad DJ, Farrar CT, Ghoshal S, Masia R, Ferreira DS, Chen YI, Choi JK, Wei L, Waghorn PA, Rotile NJ, Tu C, Graham-O'Regan KA, Sojoodi M, Li S, Li Y, Wang G, Corey KE, Or YS, Jiang L, Tanabe KK, Caravan P, Fuchs BC. Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. Hepatol Commun 2018;2:821-35. [PMID: 30027140 DOI: 10.1002/hep4.1193] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
174 Kim D, Kim W, Adejumo AC, Cholankeril G, Tighe SP, Wong RJ, Gonzalez SA, Harrison SA, Younossi ZM, Ahmed A. Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. Hepatol Int 2019;13:205-13. [PMID: 30694445 DOI: 10.1007/s12072-018-09926-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
175 Medellin A, Pridham G, Urbanski SJ, Jayakumar S, Wilson SR. Acoustic Radiation Force Impulse and Conventional Ultrasound in the Prediction of Cirrhosis Complicating Fatty Liver: Does Body Mass Index Independently Alter the Results? Ultrasound in Medicine & Biology 2019;45:3160-71. [DOI: 10.1016/j.ultrasmedbio.2019.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
176 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta. 2010;1801:299-310. [PMID: 19857603 DOI: 10.1016/j.bbalip.2009.10.007] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 13.7] [Reference Citation Analysis]
178 Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, Kuwada TS, Martinie JB, Iannitti DA, Gersin KS, Sindram D. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15-21. [PMID: 23934335 DOI: 10.1007/s11695-013-1044-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
179 Hakkak R, Gauss CH, Bell A, Korourian S. Short-Term Soy Protein Isolate Feeding Prevents Liver Steatosis and Reduces Serum ALT and AST Levels in Obese Female Zucker Rats. Biomedicines 2018;6:E55. [PMID: 29757972 DOI: 10.3390/biomedicines6020055] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
180 Zois CD, Baltayiannis GH, Bekiari A, Goussia A, Karayiannis P, Doukas M, Demopoulos D, Mitsellou A, Vougiouklakis T, Mitsi V, Tsianos EV. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 2010; 16(31): 3944-3949 [PMID: 20712056 DOI: 10.3748/wjg.v16.i31.3944] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
181 Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease: ADIPOKINES AND CYTOKINES IN NAFLD. Alimentary Pharmacology & Therapeutics 2008;27:412-21. [DOI: 10.1111/j.1365-2036.2007.03586.x] [Cited by in Crossref: 284] [Cited by in F6Publishing: 276] [Article Influence: 18.9] [Reference Citation Analysis]
182 Eifler RV. The role of ultrasonography in the measurement of subcutaneous and visceral fat and its correlation with hepatic steatosis. Radiol Bras 2013;46:273-8. [DOI: 10.1590/s0100-39842013000500002] [Cited by in Crossref: 8] [Article Influence: 0.9] [Reference Citation Analysis]
183 Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, Yao F, Sapisochin G. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation. 2018;102:640-647. [PMID: 29319620 DOI: 10.1097/tp.0000000000002043] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
184 Lim Y, Kim WR. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. Clinics in Liver Disease 2008;12:733-46. [DOI: 10.1016/j.cld.2008.07.007] [Cited by in Crossref: 187] [Cited by in F6Publishing: 176] [Article Influence: 13.4] [Reference Citation Analysis]
185 Teufel A, Itzel T, Erhart W, Brosch M, Wang XY, Kim YO, von Schönfels W, Herrmann A, Brückner S, Stickel F, Dufour JF, Chavakis T, Hellerbrand C, Spang R, Maass T, Becker T, Schreiber S, Schafmayer C, Schuppan D, Hampe J. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients. Gastroenterology 2016;151:513-525.e0. [PMID: 27318147 DOI: 10.1053/j.gastro.2016.05.051] [Cited by in Crossref: 113] [Cited by in F6Publishing: 111] [Article Influence: 18.8] [Reference Citation Analysis]
186 Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. Hepatol Commun 2020;4:998-1011. [PMID: 32626832 DOI: 10.1002/hep4.1524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
187 Tokodai K, Karadagi A, Kjaernet F, Romano A, Ericzon BG, Nowak G. Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation. Scand J Gastroenterol 2019;54:233-9. [PMID: 30999770 DOI: 10.1080/00365521.2019.1577484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
188 Qiu Z, Zhang C, Zhou J, Hu J, Sheng L, Li X, Chen L, Li X, Deng X, Zheng G. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. Mol Carcinog 2019;58:31-41. [PMID: 30182439 DOI: 10.1002/mc.22904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
189 Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Ultrasound Quarterly 2016;32:94-107. [DOI: 10.1097/ruq.0000000000000209] [Cited by in Crossref: 64] [Cited by in F6Publishing: 17] [Article Influence: 10.7] [Reference Citation Analysis]
190 Chayanupatkul M, Dasani DB, Sogaard K, Schiano TD. The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post-Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. Transplant Proc. 2020;. [PMID: 32434740 DOI: 10.1016/j.transproceed.2020.02.160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
191 Umezawa K, Kojima I, Simizu S, Lin Y, Fukatsu H, Koide N, Nakade Y, Yoneda M. Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models. Hum Cell 2018;31:95-101. [PMID: 29249016 DOI: 10.1007/s13577-017-0196-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
192 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
193 Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti L, Craxì A, Fargion S. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Clin Gastroenterol Hepatol 2017;15:1604-1611.e1. [PMID: 28554682 DOI: 10.1016/j.cgh.2017.04.045] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 13.0] [Reference Citation Analysis]
194 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
195 Hakkak R, Al-Dwairi A, Fuchs GJ, Korourian S, Simmen FA. Dietary soy protein induces hepatic lipogenic enzyme gene expression while suppressing hepatosteatosis in obese female Zucker rats bearing DMBA-initiated mammary tumors. Genes Nutr 2012;7:549-58. [PMID: 22528625 DOI: 10.1007/s12263-012-0294-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
196 Graziadei IW. Recurrence of nonviral liver diseases after liver transplantation. Clin Liver Dis. 2014;18:675-685. [PMID: 25017083 DOI: 10.1016/j.cld.2014.05.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
197 Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465. [PMID: 24745023 DOI: 10.1155/2014/741465] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
198 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152. [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 11.4] [Reference Citation Analysis]
199 Xu L, Duanmu Y, Blake GM, Zhang C, Zhang Y, Brown K, Wang X, Wang P, Zhou X, Zhang M, Wang C, Guo Z, Guglielmi G, Cheng X. Validation of goose liver fat measurement by QCT and CSE-MRI with biochemical extraction and pathology as reference. Eur Radiol 2018;28:2003-12. [PMID: 29238866 DOI: 10.1007/s00330-017-5189-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
200 Hsieh S, Leaderer BP, Feldstein AE, Santoro N, McKay LA, Caprio S, McConnell R. Traffic-related air pollution associations with cytokeratin-18, a marker of hepatocellular apoptosis, in an overweight and obese paediatric population. Pediatr Obes. 2018;13:342-347. [PMID: 28730729 DOI: 10.1111/ijpo.12228] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
201 Shiota G, Kanki K. Retinoids and their target genes in liver functions and diseases: Retinoids and their target genes. J Gastroenterol Hepatol 2013;28:33-7. [DOI: 10.1111/jgh.12031] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
202 Luo L, Li Y, Wang D, Zhao Y, Wang Y, Li F, Fang J, Chen H, Fan S, Huang C. Ginkgolide B lowers body weight and ameliorates hepatic steatosis in high-fat diet-induced obese mice correlated with pregnane X receptor activation. RSC Adv 2017;7:37858-66. [DOI: 10.1039/c7ra05621d] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
203 Yamamoto T, Nakade Y, Yamauchi T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sato K, Fukuzawa Y, Yoneda M. Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. World J Gastroenterol 2016; 22(8): 2512-2523 [PMID: 26937139 DOI: 10.3748/wjg.v22.i8.2512] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
204 Bendtsen F, Dam-larsen S. Long-Term, Clinical Follow-Up in Fatty Liver Patients. Dig Dis 2010;28:709-14. [DOI: 10.1159/000324277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
205 Siddique A, Kowdley KV. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011;15:281-96, vii-x. [PMID: 21689613 DOI: 10.1016/j.cld.2011.03.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
206 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol 2017; 9(11): 533-543 [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 79] [Cited by in F6Publishing: 76] [Article Influence: 15.8] [Reference Citation Analysis]
207 Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis. World J Gastroenterol 2014; 20(17): 4987-4993 [PMID: 24803810 DOI: 10.3748/wjg.v20.i17.4987] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
208 Rehm JL, Connor EL, Wolfgram PM, Eickhoff JC, Reeder SB, Allen DB. Predicting hepatic steatosis in a racially and ethnically diverse cohort of adolescent girls. J Pediatr 2014;165:319-325.e1. [PMID: 24857521 DOI: 10.1016/j.jpeds.2014.04.019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
209 Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15:1843-1851. [PMID: 19938117 DOI: 10.1002/lt.21943] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
210 Toriguchi K, Hatano E, Tanabe K, Takemoto K, Nakamura K, Koyama Y, Seo S, Taura K, Uemoto S. Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency. J Gastroenterol Hepatol. 2014;29:1109-1118. [PMID: 24329600 DOI: 10.1111/jgh.12481] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
211 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
212 Liao YJ, Chen TL, Lee TS, Wang HA, Wang CK, Liao LY, Liu RS, Huang SF, Chen YM. Glycine N-methyltransferase deficiency affects Niemann-Pick type C2 protein stability and regulates hepatic cholesterol homeostasis. Mol Med 2012;18:412-22. [PMID: 22183894 DOI: 10.2119/molmed.2011.00258] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
213 Alswat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol. 2013;19:144-151. [PMID: 23828743 DOI: 10.4103/1319-3767.114505] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
214 Jiang Y, Zhao M, An W. Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance. J Mol Med (Berl). 2011;89:1207-1217. [PMID: 21814826 DOI: 10.1007/s00109-011-0790-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
215 Bonacini M, Kassamali F, Kari S, Lopez Barrera N, Kohla M. Racial differences in prevalence and severity of non-alcoholic fatty liver disease. World J Hepatol 2021; 13(7): 763-773 [PMID: 34367497 DOI: 10.4254/wjh.v13.i7.763] [Reference Citation Analysis]
216 Yilmaz N, Shiffman ML. Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst. Liver Transpl. 2009;15:4-6. [PMID: 19109836 DOI: 10.1002/lt.21661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
217 Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) 2017;4:E48. [PMID: 28598410 DOI: 10.3390/children4060048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
218 Xiao CW, Wood CM, Weber D, Aziz SA, Mehta R, Griffin P, Cockell KA. Dietary supplementation with soy isoflavones or replacement with soy proteins prevents hepatic lipid droplet accumulation and alters expression of genes involved in lipid metabolism in rats. Genes Nutr 2014;9:373. [PMID: 24292949 DOI: 10.1007/s12263-013-0373-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
219 Mu J, Tan F, Zhou X, Zhao X. Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice. Food Funct 2020;11:8707-23. [PMID: 32945305 DOI: 10.1039/d0fo01823f] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
220 Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50 Suppl:S412-6. [PMID: 19074370 DOI: 10.1194/jlr.R800089-JLR200] [Cited by in Crossref: 144] [Cited by in F6Publishing: 70] [Article Influence: 10.3] [Reference Citation Analysis]
221 Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol 2008;20 Suppl 1:47-52. [PMID: 18426499 DOI: 10.1111/j.1365-2826.2008.01679.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
222 Sweet PH, Khoo T, Nguyen S. Nonalcoholic Fatty Liver Disease. Primary Care: Clinics in Office Practice 2017;44:599-607. [DOI: 10.1016/j.pop.2017.07.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
223 Schuppan D, Gorrell MD, Klein T, Mark M, Afdhal NH. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 2010;30:795-808. [PMID: 20624207 DOI: 10.1111/j.1478-3231.2010.02264.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
224 Zahmatkeshan MBG, Eshraghian A, Nikeghbalian S, Bahador A, Salahi H, Malek-Hosseini SA. De novo Fatty Liver Due to Vascular Complications After Liver Transplantation. Transplantation Proceedings. Elsevier Inc. 2011;43:615-617. [PMID: 21440778 DOI: 10.1016/j.transproceed.2011.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
225 Sangsefidi ZS, Hosseinzadeh M, Ranjbar AM, Akhondi-Meybodi M, Fallahzadeh H, Mozaffari-Khosravi H. The effect of total anthocyanin-base standardized (Cornus mas L.) fruit extract on liver function, tumor necrosis factor α, malondealdehyde, and adiponectin in patients with non-alcoholic fatty liver: a study protocol for a double-blind randomized clinical trial. Nutr J 2019;18:39. [PMID: 31324181 DOI: 10.1186/s12937-019-0465-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
226 Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, Rizzetto M. Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol. 2011;54:64-71. [PMID: 20932598 DOI: 10.1016/j.jhep.2010.06.022] [Cited by in Crossref: 158] [Cited by in F6Publishing: 152] [Article Influence: 13.2] [Reference Citation Analysis]
227 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
228 Gastaldelli A. Fatty liver disease: the hepatic manifestation of metabolic syndrome. Hypertens Res. 2010;33:546-547. [PMID: 20463681 DOI: 10.1038/hr.2010.60] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
229 Cai C, Chen DZ, Tu HX, Chen WK, Ge LC, Fu TT, Tao Y, Ye SS, Li J, Lin Z, Wang XD, Xu LM, Chen YP. MicroRNA-29c Acting on FOS Plays a Significant Role in Nonalcoholic Steatohepatitis Through the Interleukin-17 Signaling Pathway. Front Physiol 2021;12:597449. [PMID: 33927635 DOI: 10.3389/fphys.2021.597449] [Reference Citation Analysis]
230 Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. [PMID: 27633274 DOI: 10.1038/srep33386] [Cited by in Crossref: 110] [Cited by in F6Publishing: 115] [Article Influence: 18.3] [Reference Citation Analysis]
231 Della Corte C, Alisi A, Iorio R, Alterio A, Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother. 2011;12:1901-1911. [PMID: 21639814 DOI: 10.1517/14656566.2011.587123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
232 Bruce KD, Sihota KK, Byrne CD, Cagampang FR. The housekeeping gene YWHAZ remains stable in a model of developmentally primed non-alcoholic fatty liver disease. Liver Int 2012;32:1315-21. [PMID: 22583519 DOI: 10.1111/j.1478-3231.2012.02813.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
233 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
234 Yeo CM, Chong VH, Earnest A, Yang WL. Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis. World J Hepatol 2013; 5(5): 275-280 [PMID: 23717738 DOI: 10.4254/wjh.v5.i5.275] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
235 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
236 Kim D, Yoo ER, Li AA, Tighe SP, Cholankeril G, Harrison SA, Ahmed A. Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther 2019;50:590-8. [PMID: 31328300 DOI: 10.1111/apt.15395] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
237 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
238 Takeuchi H, Sugimoto K, Oshiro H, Iwatsuka K, Kono S, Yoshimasu Y, Kasai Y, Furuichi Y, Sakamaki K, Itoi T. Liver fibrosis: noninvasive assessment using supersonic shear imaging and FIB4 index in patients with non-alcoholic fatty liver disease. J Med Ultrason (2001). 2018;45:243-249. [PMID: 29128938 DOI: 10.1007/s10396-017-0840-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
239 Wang Y, Ausman LM, Russell RM, Greenberg AS, Wang XD. Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr. 2008;138:1866-1871. [PMID: 18806094 DOI: 10.1093/jn/138.10.1866] [Cited by in Crossref: 80] [Cited by in F6Publishing: 89] [Article Influence: 5.7] [Reference Citation Analysis]
240 Ong J, Younossi ZM. Non-Alcoholic Fatty Liver Disease After Liver Transplantation: A Case of Nurture and Nature. American Journal of Gastroenterology 2010;105:621-3. [DOI: 10.1038/ajg.2009.720] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
241 Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16:e34897. [PMID: 27110262 DOI: 10.5812/hepatmon.34897] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
242 Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009;9:782-793. [PMID: 19344467 DOI: 10.1111/j.1600-6143.2009.02590.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 121] [Article Influence: 10.8] [Reference Citation Analysis]
243 Zhang L, Li HX, Pan WS, Ullah Khan F, Qian C, Qi-Li FR, Xu X. Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-α. Biomed Pharmacother 2019;111:99-108. [PMID: 30579258 DOI: 10.1016/j.biopha.2018.12.059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
244 Zhou L, Yang Y, Feng Y, Zhao X, Fan Y, Rong J, Zhao L, Yu Y. Association between dietary sodium intake and non-alcoholic fatty liver disease in the US population. Public Health Nutr 2021;24:993-1000. [PMID: 32312347 DOI: 10.1017/S136898001900483X] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Gangi A, Lu SC. Chemotherapy-associated liver injury in colorectal cancer. Therap Adv Gastroenterol 2020;13:1756284820924194. [PMID: 32547639 DOI: 10.1177/1756284820924194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
246 Abbasi E, Vafaei SA, Naseri N, Darini A, Azandaryani MT, Ara FK, Mirzaei F. Protective effects of cerium oxide nanoparticles in non-alcoholic fatty liver disease (NAFLD) and carbon tetrachloride-induced liver damage in rats: Study on intestine and liver. Metabol Open 2021;12:100151. [PMID: 34870139 DOI: 10.1016/j.metop.2021.100151] [Reference Citation Analysis]
247 Xu ZJ, Fan JG, Ding XD, Qiao L, Wang GL. Characterization of high-fat, diet-induced, non-alcoholic steatohepatitis with fibrosis in rats. Dig Dis Sci. 2010;55:931-940. [PMID: 19459046 DOI: 10.1007/s10620-009-0815-3] [Cited by in Crossref: 109] [Cited by in F6Publishing: 111] [Article Influence: 8.4] [Reference Citation Analysis]
248 Jeen YM, Jin SY. [Pathology of nonalcoholic steatohepatitis]. Korean J Hepatol. 2009;15:122-130. [PMID: 19581764 DOI: 10.3350/kjhep.2009.15.2.122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
249 Daher S, Lev Cohen N, Massarwa M, Mahamid M, Nasser M, Hazou W, Oren R, Safadi R, Khoury T. Portal lymphadenopathy predicts non-alcoholic steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0207479. [PMID: 30500848 DOI: 10.1371/journal.pone.0207479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
250 Kanamori H, Nakade Y, Yamauchi T, Sakamoto K, Inoue T, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Ito K, Sumida Y, Nakao H, Fukuzawa Y, Yoneda M. Influence of nicotine on choline-deficient, L-amino acid-defined diet-induced non-alcoholic steatohepatitis in rats. PLoS One 2017;12:e0180475. [PMID: 28662136 DOI: 10.1371/journal.pone.0180475] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
251 Drescher HK, Schippers A, Clahsen T, Sahin H, Noels H, Hornef M, Wagner N, Trautwein C, Streetz KL, Kroy DC. β 7 -Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis. Journal of Hepatology 2017;66:1251-64. [DOI: 10.1016/j.jhep.2017.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
252 Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An J, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. Journal of Autoimmunity 2008;30:42-50. [DOI: 10.1016/j.jaut.2007.11.016] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
253 Guerra JFDC, Maciel PS, de Abreu ICME, Pereira RR, Silva M, Cardoso LDM, Pinheiro-sant'ana HM, Lima WGD, Silva ME, Pedrosa ML. Dietary açai attenuates hepatic steatosis via adiponectin-mediated effects on lipid metabolism in high-fat diet mice. Journal of Functional Foods 2015;14:192-202. [DOI: 10.1016/j.jff.2015.01.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.1] [Reference Citation Analysis]
254 Koopman KE, Caan MW, Nederveen AJ, Pels A, Ackermans MT, Fliers E, la Fleur SE, Serlie MJ. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Hepatology 2014;60:545-53. [PMID: 24668862 DOI: 10.1002/hep.27149] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 8.9] [Reference Citation Analysis]
255 Reichman TW, Therapondos G, Serrano MS, Seal J, Evers-Meltzer R, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D, Loss GE. “Weighing the risk”: Obesity and outcomes following liver transplantation. World J Hepatol 2015; 7(11): 1484-1493 [PMID: 26085908 DOI: 10.4254/wjh.v7.i11.1484] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
256 Stepanova M, Hossain N, Afendy A, Perry K, Goodman ZD, Baranova A, Younossi Z. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg. 2010;20:640-650. [PMID: 20119733 DOI: 10.1007/s11695-010-0078-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
257 Juárez-Hernández E, C Chávez-Tapia N, C Brizuela-Alcántara D, Uribe M, H Ramos-Ostos M, Nuño-Lámbarri N. Association Between Serum Hemoglobin Levels and Non Alcoholic Fatty Liver Disease in a Mexican Population. Ann Hepatol 2018;17:577-84. [PMID: 29893698 DOI: 10.5604/01.3001.0012.0920] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
258 Xiang Z, Chen YP, Ma KF, Ye YF, Zheng L, Yang YD, Li YM, Jin X. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013;13:140. [PMID: 24053454 DOI: 10.1186/1471-230x-13-140] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
259 Lima ML, Leite LH, Gioda CR, Leme FO, Couto CA, Coimbra CC, Leite VH, Ferrari TC. A Novel Wistar Rat Model of Obesity-Related Nonalcoholic Fatty Liver Disease Induced by Sucrose-Rich Diet. J Diabetes Res 2016;2016:9127076. [PMID: 26788524 DOI: 10.1155/2016/9127076] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
260 Liao YJ, Wang YH, Wu CY, Hsu FY, Chien CY, Lee YC. Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl4 and TAA-Induced Liver Fibrosis in Mice. Int J Mol Sci 2021;22:2934. [PMID: 33805788 DOI: 10.3390/ijms22062934] [Reference Citation Analysis]
261 Sutter AG, Palanisamy AP, Ellet JD, Schmidt MG, Schnellmann RG, Chavin KD. Intereukin-10 and Kupffer cells protect steatotic mice livers from ischemia-reperfusion injury. Eur Cytokine Netw. 2014;25:69-76. [PMID: 25679269 DOI: 10.1684/ecn.2015.0359] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
262 Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Kim KJ, Han K. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2017;62:2150-8. [DOI: 10.1007/s10620-017-4592-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
263 Sikder K, Kesh SB, Das N, Manna K, Dey S. The high antioxidative power of quercetin (aglycone flavonoid) and its glycone (rutin) avert high cholesterol diet induced hepatotoxicity and inflammation in Swiss albino mice. Food Funct 2014;5:1294. [DOI: 10.1039/c3fo60526d] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
264 Wang Y, Seitz HK, Wang XD. Moderate alcohol consumption aggravates high-fat diet induced steatohepatitis in rats. Alcohol Clin Exp Res. 2010;34:567-573. [PMID: 20028348 DOI: 10.1111/j.1530-0277.2009.01122.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
265 Kramer H, Cao G, Dugas L, Luke A, Cooper R, Durazo-arvizu R. Increasing BMI and waist circumference and prevalence of obesity among adults with Type 2 diabetes: the National Health and Nutrition Examination Surveys. Journal of Diabetes and its Complications 2010;24:368-74. [DOI: 10.1016/j.jdiacomp.2009.10.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
266 Younossi ZM, Afendy A, Stepanova M, Hossain N, Younossi I, Ankrah K, Gramlich T, Baranova A. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int 2009;29:1403-12. [PMID: 19515216 DOI: 10.1111/j.1478-3231.2009.02060.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
267 Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, Matsushita K, Imazeki F, Yokosuka O, Nomura F. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol 2013;13:120. [PMID: 23875831 DOI: 10.1186/1471-230X-13-120] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
268 Ren T, Zhu J, Zhu L, Cheng M. The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α. Nutrients 2017;9:E198. [PMID: 28264426 DOI: 10.3390/nu9030198] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
269 Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9:616-622. [PMID: 18763311 DOI: 10.1631/jzus.b0720016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
270 Imai Y, Boyle S, Varela GM, Caron E, Yin X, Dhir R, Dhir R, Graham MJ, Ahima RS. Effects of perilipin 2 antisense oligonucleotide treatment on hepatic lipid metabolism and gene expression. Physiol Genomics 2012;44:1125-31. [PMID: 23012396 DOI: 10.1152/physiolgenomics.00045.2012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
271 Kim D, Kim W, Kwak MS, Chung GE, Yim JY, Ahmed A. Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. PLoS One. 2017;12:e0186702. [PMID: 29049354 DOI: 10.1371/journal.pone.0186702] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
272 Sun W, Liu P, Yang B, Wang M, Wang T, Sun W, Wang X, Zheng W, Song X, Li J. A network pharmacology approach: Inhibition of the NF-κB signaling pathway contributes to the NASH preventative effect of an Oroxylum indicum seed extract in oleic acid-stimulated HepG2 cells and high-fat diet-fed rats. Phytomedicine 2021;88:153498. [PMID: 33640247 DOI: 10.1016/j.phymed.2021.153498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874-1882. [PMID: 21360720 DOI: 10.1002/hep.24268] [Cited by in Crossref: 401] [Cited by in F6Publishing: 359] [Article Influence: 36.5] [Reference Citation Analysis]
274 Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015;42:1051-1063. [PMID: 26304302 DOI: 10.1111/apt.13376] [Cited by in Crossref: 102] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
275 Zhang C, Liu Y, Li HZ, Yang XC, Zhou GL, Wu WY, Wang M, Xiong P. Predictive significance of normal serum alanine aminotransferase in patients with nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2011; 19(8): 841-844 [DOI: 10.11569/wcjd.v19.i8.841] [Reference Citation Analysis]
276 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015; 21(39): 11077-11087 [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
277 Nazal L, Riquelme A, Solís N, Pizarro M, Escalona A, Burotto M, Méndez JI, Saint-Jean C, Concha MJ, Giovanni S. Hypoadiponectinemia and its association with liver fibrosis in morbidly obese patients. Obes Surg. 2010;20:1400-1407. [PMID: 20066503 DOI: 10.1007/s11695-009-0051-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
278 Selby LV, Ejaz A, Brethauer SA, Pawlik TM. Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. Expert Opin Investig Drugs 2020;29:107-10. [PMID: 31986920 DOI: 10.1080/13543784.2020.1721457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]